Skip to content
Review

Critical complications of CAR T-cell therapy: an interdisciplinary approach to early diagnosis and critical care

Oct 2026 · Astana Medical Journal · Vol 126, pp. amj040 · 0 citations

TL;DR

The review addresses cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infection and sepsis, acute organ dysfunction, prolonged cytopenias, and secondary immunodeficiency to synthesize current evidence on their early diagnosis, monitoring, critical care, and interdisciplinary management.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed and refractory hematologic malignancies but can cause rapidly progressive inflammatory, neurologic, infectious, hematologic, cardiovascular, respiratory, and renal complications with overlapping clinical manifestations. This review aimed to synthesize current evidence on their early diagnosis, monitoring, critical care, and interdisciplinary management. A targeted narrative search was conducted in PubMed, including MEDLINE-indexed records, Google Scholar, and websites of international professional societies; the last search was performed on 30 September 2026. The structured PubMed strategy retrieved 4,178 records. Publications from January 2016 through September 2026 were considered, together with two earlier foundational guidelines on febrile neutropenia and acute kidney injury. Thirty-five sources were included after title/abstract screening and targeted full-text assessment. The review addresses cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infection and sepsis, acute organ dysfunction, prolonged cytopenias, and secondary immunodeficiency. Standardized toxicity grading, serial neurologic assessment, and continuous evaluation of hemodynamics, oxygenation, fluid balance, renal function, coagulation, ferritin, fibrinogen, blood cell counts, and microbiological findings are central to early recognition of deterioration. Fever and organ dysfunction require simultaneous evaluation for immune-mediated toxicity and infection because these conditions may coexist and no single biomarker reliably excludes sepsis. Management should combine syndrome-directed anti-inflammatory treatment, prompt empirical antimicrobial therapy when indicated, and timely organ support. Advanced support outside the intensive care unit is an organizational exception rather than an evidence-proven equivalent model and must not delay transfer. Predefined escalation pathways and coordinated multidisciplinary care are essential for safe implementation of CAR T-cell therapy. Keywords: receptors, chimeric antigen, immunotherapy, adoptive, cytokine release syndrome, neurotoxicity syndromes, critical care, sepsis, patient care team.

View source

Similar papers

Review Open access Oct 2026

Advancing CAR-T Cell Therapy: Biomarker Discovery and Toxicity Management in Pediatric and Young-Adult Populations

CAR-T cell therapy has substantially improved treatment options for relapsed or refractory hematologic malignancies, but clinically important toxicities remain, particularly cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and treatment-related cytopenias. This article pr...

J. Odongo · 0 citations
Review Open access Oct 2026

Immune checkpoint inhibitors and the clinical management of immune-related toxicities

Immune checkpoint inhibitors have expanded the treatment of solid and hematologic malignancies, but the same release of inhibitory T-cell signaling can provoke inflammatory injury in almost any organ. This narrative critical review examines how immune-related adverse events should be recognized, differentiated from com...

Marina Ribeiro Fernandes Oliveira, Melissa de Carvalho Santuchi, L. Carvalho et al. · 0 citations
Review Sep 2026

Clinical management strategies for cytokine release syndrome and their impact on CAR T-cell efficacy in lymphoma.

Chimeric antigen receptor T-cell (CAR-T) therapy has significantly advanced the treatment of relapsed/refractory (R/R) lymphoma. However, its broader clinical application is often limited by cytokine release syndrome (CRS), a major immune-mediated complication. Because the in vivo expansion of CAR-T cells drives both t...

Kai-Hang Shi, Xue-Yan Sun, Gao-Xiang Wang · 0 citations
Review Open access Sep 2026

Modern Approaches to the Diagnosis and Treatment of Cytokine Release Syndrome Following CAR T-Cell Therapy

Introduction. Oncological diseases remain one of the leading causes of mortality worldwide. CAR T-cell therapy has demonstrated high efficacy in the treatment of B-cell leukaemias, lymphomas, and multiple myeloma. However, it is associated with a high risk of cytokine release syndrome, which occurs in approximately 55....

Alexander M. Tsurkan, Darya V. Shpakova, T. V. Ulanova · 0 citations
Review Open access Oct 2026

Early Toxicities of CAR-T Cell Therapy: Mechanisms, Prediction, and Management

Chimeric antigen receptor T (CAR-T) cell therapy has completely reshaped the therapeutic landscape for some blood cancers, including B-cell lymphoma, myeloma, and acute lymphoblastic leukemia. However, the complications associated with this powerful therapy are preventing it from being used more widely. This review exp...

Swathi Srikantan, Alexander Weiss, Zainab Muslehuddin et al. · 0 citations
Review Open access Oct 2026

Chimeric antigen receptor t-cell therapy for systemic autoimmune diseases: a systematic review

Emerging evidence suggests CAR T-cell therapy is associated with rapid, sustained clinical remission in severe, refractory cases, particularly Systemic Lupus Erythematosus, and demonstrates promise as a novel therapeutic strategy for refractory autoimmune diseases.

UF Ofodile, D. Davidson, OH Ezemaduka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.